GoodRx (NASDAQ:GDRX) PT Raised to $10.00

GoodRx (NASDAQ:GDRX - Get Free Report) had its price objective lifted by stock analysts at Barclays from $9.00 to $10.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Barclays's price objective points to a potential upside of 40.25% from the stock's current price.

Other analysts have also issued research reports about the stock. SVB Leerink started coverage on shares of GoodRx in a research note on Monday, February 26th. They issued an "outperform" rating and a $8.00 target price for the company. Truist Financial increased their price objective on shares of GoodRx from $7.50 to $8.00 and gave the company a "hold" rating in a research note on Friday, March 1st. Wells Fargo & Company upgraded GoodRx from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $7.50 to $10.00 in a research note on Monday, March 25th. KeyCorp raised GoodRx from a "sector weight" rating to an "overweight" rating and set a $9.00 target price for the company in a report on Wednesday, April 10th. Finally, Raymond James upgraded GoodRx from a "market perform" rating to an "outperform" rating and set a $10.00 price target on the stock in a report on Thursday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $9.00.

GoodRx Stock Down 4.7 %

Shares of NASDAQ:GDRX traded down $0.35 during midday trading on Monday, hitting $7.13. 1,712,510 shares of the company's stock were exchanged, compared to its average volume of 1,562,651. The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. GoodRx has a 12 month low of $4.14 and a 12 month high of $9.37. The company has a market cap of $2.68 billion, a PE ratio of -712.29, a price-to-earnings-growth ratio of 3.05 and a beta of 1.37. The stock has a 50 day moving average price of $6.96 and a 200-day moving average price of $6.49.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.02 EPS for the quarter, hitting analysts' consensus estimates of $0.02. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The firm had revenue of $196.64 million during the quarter, compared to analyst estimates of $195.59 million. On average, sell-side analysts anticipate that GoodRx will post 0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

A number of institutional investors have recently added to or reduced their stakes in the business. Dark Forest Capital Management LP bought a new stake in GoodRx during the 3rd quarter valued at approximately $2,454,000. Gotham Asset Management LLC grew its position in GoodRx by 121.6% in the 3rd quarter. Gotham Asset Management LLC now owns 72,090 shares of the company's stock worth $406,000 after purchasing an additional 39,552 shares during the period. Citigroup Inc. increased its position in GoodRx by 301.7% during the third quarter. Citigroup Inc. now owns 7,997 shares of the company's stock valued at $45,000 after acquiring an additional 6,006 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of GoodRx by 2.1% in the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company's stock worth $48,875,000 after buying an additional 177,961 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. bought a new stake in GoodRx during the third quarter valued at about $8,866,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.